RTP Mobile Logo
Cancer Educators Slide Library: Dermatologic Complications of Systemic Anticancer Therapy
Released August 2010

A comprehensive online training resource and self-directed interactive educational activity on the clinical implications and supportive management of cancer treatment-induced dermatologic side effects. Seminar I features Dr Mario E Lacouture discussing the dermatologic toxicities of various systemic anticancer therapies. (Video Content)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical oncologists, hematologists and hematology-oncology fellows.

    LEARNING OBJECTIVES

    • Differentiate between the clinical features of dermatologic side effects associated with the use of capecitabine and EGFR and multikinase (MK) inhibitors.
    • Counsel patients receiving capecitabine, EGFR inhibitors or MK inhibitors about the incidence of treatment-related dermatotoxicities, and offer supportive tactics to reduce the risk and severity of anticipated skin reactions.
    • Employ evidence- and/or consensus-based guidelines when recommending effective topical and systemic interventions for hand-foot skin reactions characteristic of MK inhibitor therapy.
    • Identify patients with classic EGFR inhibitor-associated papulopustular skin rash who may harbor or are particularly prone to acquiring secondary infections at the site of the toxic effect.
    • Facilitate adherence to capecitabine through early recognition and management of palmar-plantar erythrodysesthesia.
    • Appraise the clinical implications of emerging data demonstrating skin rash to be a biomarker of response to EGFR inhibitor treatment.
    • Develop best-practice supportive management algorithms to classify and palliate cancer treatment-induced dermatologic side effects.
    • Recognize the physical and psychosocial challenges faced by patients with moderate to severe dermatotoxicity, and communicate the importance of continued medication compliance.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains a video component. The participant should watch the video.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Mario E Lacouture, MD
    Dermatology Service
    Department of Medicine
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Onyx Pharmaceuticals Inc, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Wyeth.

    MODERATOR
    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Amgen Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Bristol-Myers Squibb Company and Genentech BioOncology.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2010
    Expiration date: October 2011

Acknowledge and close

Watch video
(WIFI is recommended for best performance):